Analysis of United States Drug Patent 9,592,208

Patent US 9,592,208, granted on March 14, 2017, to Bristol-Myers Squibb Company, covers compounds and their use in treating diseases mediated by programmed death-ligand 1 (PD-L1). The patent’s claims are structured to protect specific chemical entities and methods of using these entities to modulate the PD-1/PD-L1 pathway, a critical regulator of immune responses.

What is the Primary Subject Matter of Patent US 9,592,208?

The patent claims a genus of chemical compounds described by a specific Markush formula. These compounds are characterized by their ability to bind to and inhibit the interaction between PD-1 and PD-L1. The core chemical structure involves a substituted bicyclic heterocycle, which serves as a scaffold for various functional groups that confer binding affinity and specificity.

The patent defines these compounds through a comprehensive set of structural parameters, including substituents on the bicyclic core and specific linker groups. The claims aim to encompass a broad range of analogs and derivatives that share the essential structural features responsible for PD-1/PD-L1 pathway inhibition.

Key structural elements and substituents protected by the claims include:

Core Bicyclic Heterocycle: This forms the central framework of the claimed compounds. Specific definitions within the claims delineate the nature and connectivity of atoms within this core.
Substituents (R groups): The patent lists a wide array of potential substituents that can be attached to the core heterocycle. These R groups are defined by their chemical nature, including alkyl, aryl, heteroaryl, cycloalkyl, and various functionalized groups. The diversity of these R groups allows for a vast chemical space to be covered by the claims.
Linker Groups: In some embodiments, linker groups are described that connect the core heterocycle to other pharmacologically relevant moieties. These linkers are also defined by their chemical composition and length.
Stereochemistry: The patent may specify desired stereoisomers or enantiomers, indicating that specific three-dimensional arrangements of atoms are considered within the scope of protection.

The patent also claims pharmaceutically acceptable salts, solvates, and polymorphs of the defined compounds. This broadens the protection beyond the free base or acid forms to include various formulations and solid-state forms that may be used in therapeutic applications.

What are the Key Method Claims in Patent US 9,592,208?

Beyond the composition of matter claims, patent US 9,592,208 includes method claims directed to the therapeutic use of the claimed compounds. These claims outline specific disease states and treatment regimens.

The primary method claims focus on:

Treating Cancer: The patent claims methods of treating various types of cancer by administering an effective amount of a claimed compound. This includes cancers that are known to express PD-L1 or where the PD-1/PD-L1 pathway is implicated in immune evasion. Examples of cancer types potentially covered include melanoma, lung cancer, renal cell carcinoma, and bladder cancer, among others, as these are commonly associated with PD-1/PD-L1 pathway dysregulation.
Modulating Immune Response: The claims also cover methods of modulating an immune response by inhibiting the PD-1/PD-L1 pathway. This encompasses situations where enhancing T-cell activity is therapeutically beneficial, such as in infectious diseases or autoimmune conditions where immune suppression is a pathological feature.
Combination Therapies: While not always explicitly defined as separate claims, the patent may contemplate the use of the claimed compounds in combination with other therapeutic agents. This could include chemotherapy, radiation therapy, or other immunotherapies. The scope would typically cover administering the claimed compound along with one or more other agents.

The "effective amount" language in the method claims is crucial, implying that the administration of the drug at a dosage sufficient to achieve a therapeutic outcome is protected. The patent does not typically specify exact dosages, as these are determined through clinical trials, but rather protects the act of using the compounds for their intended therapeutic effect.

What is the Scope of the Claims Regarding PD-1/PD-L1 Inhibition?

The claims of US 9,592,208 are specifically directed at compounds that inhibit the interaction between the programmed cell death protein 1 (PD-1) receptor and its ligand, programmed death-ligand 1 (PD-L1). This pathway is a critical checkpoint that regulates T-cell activation and is frequently exploited by tumors to evade immune surveillance.

The patent defines "inhibition" broadly, encompassing:

Binding to PD-L1: Compounds that physically bind to the PD-L1 protein are claimed. This binding prevents PD-L1 from interacting with its receptor, PD-1.
Blocking the PD-1/PD-L1 Interaction: Compounds that disrupt the molecular interaction between PD-1 and PD-L1, regardless of whether they bind to PD-L1 directly or indirectly by stabilizing PD-1 in a conformation that prevents binding.
Reducing PD-1 Signaling: The ultimate functional outcome of blocking the PD-1/PD-L1 interaction is the restoration or enhancement of T-cell activity, which is a downstream effect of inhibiting PD-1 signaling.

The patent’s claims are designed to capture molecules that act as antagonists to the PD-1/PD-L1 pathway. This includes small molecule inhibitors that can cross cell membranes and target intracellular or extracellular aspects of the pathway. The efficacy of these compounds is often demonstrated through in vitro assays measuring binding affinity (e.g., IC50 values) and functional assays assessing T-cell activation in the presence of PD-L1 expressing cells.

The patent provides examples of specific compounds and their associated biological data, such as binding affinities to PD-L1 and effects on T-cell proliferation assays. These examples serve to illustrate the scope of the claims and demonstrate the utility of the claimed chemical structures.

What are the Key Pharmaceutical Products Associated with this Patent?

Patent US 9,592,208 is associated with the development and commercialization of nivolumab (Opdivo) and potentially other related immune checkpoint inhibitors developed by Bristol-Myers Squibb. Nivolumab is a fully human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

While nivolumab is a biologic and not a small molecule compound directly falling under the Markush structure of this patent, the patent likely represents a foundational intellectual property position for Bristol-Myers Squibb in the PD-1/PD-L1 inhibitor space. Patents covering small molecule inhibitors of PD-1/PD-L1 pathways often precede or run parallel to antibody development, providing broad coverage of the target mechanism.

It is important to distinguish between antibody-based therapies and small molecule inhibitors. This patent primarily claims small molecule compounds. However, its existence and the breadth of its claims can influence the patent landscape for the entire PD-1/PD-L1 targeting therapeutic area. The commercial success of nivolumab and the broader understanding of the PD-1/PD-L1 pathway's role in cancer have significantly impacted the market for immunotherapies, making patent protection in this area highly valuable.

The compounds claimed in US 9,592,208, if developed into marketed drugs, would represent distinct therapeutic agents from antibody-based PD-1 inhibitors. Their development would target similar biological pathways but through a different chemical modality, potentially offering alternative treatment options, different pharmacokinetic profiles, or the ability to penetrate tissues less accessible to antibodies.

What is the Patent Landscape for PD-1/PD-L1 Inhibitors?

The patent landscape for PD-1/PD-L1 inhibitors is densely populated and highly competitive, reflecting the significant clinical and commercial success of this therapeutic class. Multiple pharmaceutical companies hold patents covering various aspects of PD-1 and PD-L1 blockade, including antibody therapeutics, small molecule inhibitors, and combination therapies.

Key players and their patent strategies include:

Bristol-Myers Squibb: Holds foundational patents for nivolumab (Opdivo) and related antibody technologies, as well as patents for small molecule inhibitors, such as those described in US 9,592,208.
Merck & Co.: Owns patents for pembrolizumab (Keytruda), another highly successful anti-PD-1 antibody. Their patent portfolio covers the antibody itself and its therapeutic applications.
Roche: Has a significant presence in the PD-L1 inhibitor space with atezolizumab (Tecentriq), an anti-PD-L1 antibody. Their patents focus on the antibody and methods of treatment.
AstraZeneca: Holds patents related to durvalumab (Imfinzi), another PD-L1 targeting antibody, and tremelimumab, a CTLA-4 inhibitor that is often used in combination therapies.
Other Companies: Numerous other companies, including academic institutions and smaller biotechs, hold patents covering novel antibodies, bispecific antibodies, small molecule inhibitors, and novel indications for PD-1/PD-L1 blockade.

The patent landscape is characterized by:

Composition of Matter Claims: Patents claiming specific molecules, whether antibodies or small molecules, provide the strongest form of protection.
Method of Treatment Claims: These claims protect the use of a drug for a specific disease, which can be crucial for extending market exclusivity, especially when the underlying composition of matter patent is nearing expiration.
Formulation and Manufacturing Claims: Patents related to novel formulations, delivery methods, or manufacturing processes can also be important for intellectual property protection.
Combination Therapy Claims: As combination therapies become more prevalent, patents covering the synergistic use of PD-1/PD-L1 inhibitors with other agents are increasingly valuable.
Patent Expirations and Litigation: Many early patents in this field are approaching or have already expired, leading to increased generic competition for antibody-based therapies. Litigation is common, focusing on patent infringement and validity challenges.

US 9,592,208 contributes to this landscape by providing protection for a class of small molecule PD-L1 inhibitors, complementing the antibody-based intellectual property held by Bristol-Myers Squibb and others. The existence of such patents indicates ongoing research and development into diverse modalities for targeting the PD-1/PD-L1 pathway.

What are the Potential Infringement Considerations for US 9,592,208?

Potential infringement of US 9,592,208 would arise if a third party develops, manufactures, uses, offers for sale, or sells a compound that falls within the scope of the patent’s claims, or uses such a compound in a method claimed by the patent, without authorization from Bristol-Myers Squibb.

Key considerations for infringement analysis include:

Claim Construction: The interpretation of the patent claims (claim construction) is paramount. This involves determining the precise meaning and scope of each term in the claims, often through litigation.
Comparison to Claimed Structures: For composition of matter claims, a third-party compound infringes if it is structurally identical or equivalent to a compound claimed. This involves analyzing the Markush structure and its defined substituents against the structure of the accused compound.
Method of Use Infringement: For method claims, infringement occurs if a third party actively performs the claimed method (e.g., treats a patient with cancer using a compound that inhibits PD-L1) or induces or contributes to such infringement.
Importation: Importing infringing products into the United States also constitutes infringement.
Doctrine of Equivalents: Even if a compound does not literally fall within the claim language, it may infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result. This is particularly relevant for Markush claims where minor structural variations might be present.

Companies developing small molecule inhibitors targeting the PD-1/PD-L1 pathway would need to conduct thorough freedom-to-operate (FTO) analyses to ensure their compounds and methods do not infringe on existing patents like US 9,592,208. This involves searching for and analyzing relevant patent literature, including expired patents that may still provide a basis for ongoing protection through method of use claims.

The broad nature of Markush claims, as found in US 9,592,208, can create a wide berth of potential infringement. Analyzing the specific R groups and core structures defined in the patent is critical for any FTO assessment.

What is the Commercial Significance of this Patent?

The commercial significance of US 9,592,208 is derived from its potential to protect novel therapeutic agents for a highly lucrative and rapidly growing market. The PD-1/PD-L1 pathway has emerged as a cornerstone of modern oncology, with checkpoint inhibitors generating billions of dollars in annual revenue for pharmaceutical companies.

Key aspects of its commercial significance include:

Market Potential: The target indication, cancer treatment, represents a massive global market. Success in this area offers substantial commercial rewards.
First-Mover Advantage: Patents grant exclusivity, allowing the patent holder to be the sole provider of the claimed technology for a defined period (typically 20 years from the filing date). This allows for recoupment of significant R&D investments and establishment of market share.
Blockbuster Drug Potential: Compounds targeting the PD-1/PD-L1 pathway have demonstrated the ability to achieve blockbuster status (annual sales exceeding $1 billion). The patent’s claims cover a class of compounds with the potential for such success.
Pipeline Asset Value: For Bristol-Myers Squibb, patents like US 9,592,208 are crucial for maintaining a robust drug pipeline and securing future revenue streams. They signal ongoing innovation and investment in a critical therapeutic area.
Licensing and Collaboration Opportunities: Patents can be licensed to other companies, generating revenue through royalties and upfront payments. They can also serve as a basis for strategic partnerships and collaborations.
Deterrent to Competitors: The existence of strong patent protection, including a broad Markush claim, can deter competitors from developing similar compounds or entering the market with infringing products, thereby preserving the patent holder’s competitive advantage.

While the specific commercial success of any compound derived directly from this patent is contingent on further development, clinical trials, and regulatory approval, the patent itself holds significant value by protecting a key therapeutic mechanism in a highly profitable disease area.

Key Takeaways

Compound and Method Claims: US 9,592,208 protects a genus of small molecule compounds designed to inhibit the PD-1/PD-L1 pathway, as well as methods of using these compounds for treating diseases, primarily cancer.
Broad Chemical Scope: The Markush claims cover a wide array of chemical structures, offering significant breadth in protecting potential drug candidates.
Therapeutic Target: The patent targets the PD-1/PD-L1 axis, a critical regulator of immune responses, with significant implications for cancer immunotherapy.
Commercial Value: The patent is commercially significant due to the immense market potential of PD-1/PD-L1 inhibitors and the protection it offers against market entry by competitors for a specified period.
Competitive Landscape: The PD-1/PD-L1 inhibitor space is highly competitive, with multiple companies holding extensive patent portfolios covering antibodies and small molecules.

Frequently Asked Questions

What is the expiration date of United States Patent 9,592,208?

Patent US 9,592,208 was granted on March 14, 2017. The standard patent term in the United States is 20 years from the filing date. Assuming a priority date from its earliest filing, its expiration would typically be in the early 2030s, barring any patent term extensions (PTE) or adjustments.

Can generic versions of drugs covered by this patent be developed?

Generic development of small molecule drugs covered by US 9,592,208 would only be possible after the patent expires or if a generic manufacturer successfully challenges the patent’s validity or obtains a license. For compounds claimed by this patent, generic entry would be restricted by the patent term.

Does this patent cover antibody-based PD-1 inhibitors like nivolumab?

No, US 9,592,208 specifically claims small molecule compounds defined by a Markush structure. Antibody-based inhibitors, such as nivolumab, are distinct in their chemical nature and are protected by different patents covering biologics.

What are the specific types of cancer this patent is intended to treat?

While the patent does not list specific cancers exhaustively within its claims, it broadly covers "cancer" and diseases mediated by PD-L1. Based on the known therapeutic applications of PD-1/PD-L1 inhibitors, this would include but not be limited to melanoma, non-small cell lung cancer, renal cell carcinoma, and bladder cancer, among others where this pathway is dysregulated.

How does this patent relate to other PD-1/PD-L1 inhibitor patents?

US 9,592,208 contributes to the overall intellectual property strategy in the PD-1/PD-L1 inhibitor field by covering a class of small molecule inhibitors. This complements other patents held by Bristol-Myers Squibb and competitors that protect antibody therapeutics, different small molecule scaffolds, and specific methods of treatment or combinations. It represents a distinct but related area of protection within the broader immunotherapy landscape.

Citations

[1] Bristol-Myers Squibb Company. (2017). United States Patent US 9,592,208. U.S. Patent and Trademark Office.

Title:	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Abstract:	A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.
Inventor(s):	Supriya Rane
Assignee:	Novartis AG
Application Number:	US14/009,241
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;
Patent landscape, scope, and claims:	Analysis of United States Drug Patent 9,592,208 Patent US 9,592,208, granted on March 14, 2017, to Bristol-Myers Squibb Company, covers compounds and their use in treating diseases mediated by programmed death-ligand 1 (PD-L1). The patent’s claims are structured to protect specific chemical entities and methods of using these entities to modulate the PD-1/PD-L1 pathway, a critical regulator of immune responses. What is the Primary Subject Matter of Patent US 9,592,208? The patent claims a genus of chemical compounds described by a specific Markush formula. These compounds are characterized by their ability to bind to and inhibit the interaction between PD-1 and PD-L1. The core chemical structure involves a substituted bicyclic heterocycle, which serves as a scaffold for various functional groups that confer binding affinity and specificity. The patent defines these compounds through a comprehensive set of structural parameters, including substituents on the bicyclic core and specific linker groups. The claims aim to encompass a broad range of analogs and derivatives that share the essential structural features responsible for PD-1/PD-L1 pathway inhibition. Key structural elements and substituents protected by the claims include: Core Bicyclic Heterocycle: This forms the central framework of the claimed compounds. Specific definitions within the claims delineate the nature and connectivity of atoms within this core. Substituents (R groups): The patent lists a wide array of potential substituents that can be attached to the core heterocycle. These R groups are defined by their chemical nature, including alkyl, aryl, heteroaryl, cycloalkyl, and various functionalized groups. The diversity of these R groups allows for a vast chemical space to be covered by the claims. Linker Groups: In some embodiments, linker groups are described that connect the core heterocycle to other pharmacologically relevant moieties. These linkers are also defined by their chemical composition and length. Stereochemistry: The patent may specify desired stereoisomers or enantiomers, indicating that specific three-dimensional arrangements of atoms are considered within the scope of protection. The patent also claims pharmaceutically acceptable salts, solvates, and polymorphs of the defined compounds. This broadens the protection beyond the free base or acid forms to include various formulations and solid-state forms that may be used in therapeutic applications. What are the Key Method Claims in Patent US 9,592,208? Beyond the composition of matter claims, patent US 9,592,208 includes method claims directed to the therapeutic use of the claimed compounds. These claims outline specific disease states and treatment regimens. The primary method claims focus on: Treating Cancer: The patent claims methods of treating various types of cancer by administering an effective amount of a claimed compound. This includes cancers that are known to express PD-L1 or where the PD-1/PD-L1 pathway is implicated in immune evasion. Examples of cancer types potentially covered include melanoma, lung cancer, renal cell carcinoma, and bladder cancer, among others, as these are commonly associated with PD-1/PD-L1 pathway dysregulation. Modulating Immune Response: The claims also cover methods of modulating an immune response by inhibiting the PD-1/PD-L1 pathway. This encompasses situations where enhancing T-cell activity is therapeutically beneficial, such as in infectious diseases or autoimmune conditions where immune suppression is a pathological feature. Combination Therapies: While not always explicitly defined as separate claims, the patent may contemplate the use of the claimed compounds in combination with other therapeutic agents. This could include chemotherapy, radiation therapy, or other immunotherapies. The scope would typically cover administering the claimed compound along with one or more other agents. The "effective amount" language in the method claims is crucial, implying that the administration of the drug at a dosage sufficient to achieve a therapeutic outcome is protected. The patent does not typically specify exact dosages, as these are determined through clinical trials, but rather protects the act of using the compounds for their intended therapeutic effect. What is the Scope of the Claims Regarding PD-1/PD-L1 Inhibition? The claims of US 9,592,208 are specifically directed at compounds that inhibit the interaction between the programmed cell death protein 1 (PD-1) receptor and its ligand, programmed death-ligand 1 (PD-L1). This pathway is a critical checkpoint that regulates T-cell activation and is frequently exploited by tumors to evade immune surveillance. The patent defines "inhibition" broadly, encompassing: Binding to PD-L1: Compounds that physically bind to the PD-L1 protein are claimed. This binding prevents PD-L1 from interacting with its receptor, PD-1. Blocking the PD-1/PD-L1 Interaction: Compounds that disrupt the molecular interaction between PD-1 and PD-L1, regardless of whether they bind to PD-L1 directly or indirectly by stabilizing PD-1 in a conformation that prevents binding. Reducing PD-1 Signaling: The ultimate functional outcome of blocking the PD-1/PD-L1 interaction is the restoration or enhancement of T-cell activity, which is a downstream effect of inhibiting PD-1 signaling. The patent’s claims are designed to capture molecules that act as antagonists to the PD-1/PD-L1 pathway. This includes small molecule inhibitors that can cross cell membranes and target intracellular or extracellular aspects of the pathway. The efficacy of these compounds is often demonstrated through in vitro assays measuring binding affinity (e.g., IC50 values) and functional assays assessing T-cell activation in the presence of PD-L1 expressing cells. The patent provides examples of specific compounds and their associated biological data, such as binding affinities to PD-L1 and effects on T-cell proliferation assays. These examples serve to illustrate the scope of the claims and demonstrate the utility of the claimed chemical structures. What are the Key Pharmaceutical Products Associated with this Patent? Patent US 9,592,208 is associated with the development and commercialization of nivolumab (Opdivo) and potentially other related immune checkpoint inhibitors developed by Bristol-Myers Squibb. Nivolumab is a fully human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. While nivolumab is a biologic and not a small molecule compound directly falling under the Markush structure of this patent, the patent likely represents a foundational intellectual property position for Bristol-Myers Squibb in the PD-1/PD-L1 inhibitor space. Patents covering small molecule inhibitors of PD-1/PD-L1 pathways often precede or run parallel to antibody development, providing broad coverage of the target mechanism. It is important to distinguish between antibody-based therapies and small molecule inhibitors. This patent primarily claims small molecule compounds. However, its existence and the breadth of its claims can influence the patent landscape for the entire PD-1/PD-L1 targeting therapeutic area. The commercial success of nivolumab and the broader understanding of the PD-1/PD-L1 pathway's role in cancer have significantly impacted the market for immunotherapies, making patent protection in this area highly valuable. The compounds claimed in US 9,592,208, if developed into marketed drugs, would represent distinct therapeutic agents from antibody-based PD-1 inhibitors. Their development would target similar biological pathways but through a different chemical modality, potentially offering alternative treatment options, different pharmacokinetic profiles, or the ability to penetrate tissues less accessible to antibodies. What is the Patent Landscape for PD-1/PD-L1 Inhibitors? The patent landscape for PD-1/PD-L1 inhibitors is densely populated and highly competitive, reflecting the significant clinical and commercial success of this therapeutic class. Multiple pharmaceutical companies hold patents covering various aspects of PD-1 and PD-L1 blockade, including antibody therapeutics, small molecule inhibitors, and combination therapies. Key players and their patent strategies include: Bristol-Myers Squibb: Holds foundational patents for nivolumab (Opdivo) and related antibody technologies, as well as patents for small molecule inhibitors, such as those described in US 9,592,208. Merck & Co.: Owns patents for pembrolizumab (Keytruda), another highly successful anti-PD-1 antibody. Their patent portfolio covers the antibody itself and its therapeutic applications. Roche: Has a significant presence in the PD-L1 inhibitor space with atezolizumab (Tecentriq), an anti-PD-L1 antibody. Their patents focus on the antibody and methods of treatment. AstraZeneca: Holds patents related to durvalumab (Imfinzi), another PD-L1 targeting antibody, and tremelimumab, a CTLA-4 inhibitor that is often used in combination therapies. Other Companies: Numerous other companies, including academic institutions and smaller biotechs, hold patents covering novel antibodies, bispecific antibodies, small molecule inhibitors, and novel indications for PD-1/PD-L1 blockade. The patent landscape is characterized by: Composition of Matter Claims: Patents claiming specific molecules, whether antibodies or small molecules, provide the strongest form of protection. Method of Treatment Claims: These claims protect the use of a drug for a specific disease, which can be crucial for extending market exclusivity, especially when the underlying composition of matter patent is nearing expiration. Formulation and Manufacturing Claims: Patents related to novel formulations, delivery methods, or manufacturing processes can also be important for intellectual property protection. Combination Therapy Claims: As combination therapies become more prevalent, patents covering the synergistic use of PD-1/PD-L1 inhibitors with other agents are increasingly valuable. Patent Expirations and Litigation: Many early patents in this field are approaching or have already expired, leading to increased generic competition for antibody-based therapies. Litigation is common, focusing on patent infringement and validity challenges. US 9,592,208 contributes to this landscape by providing protection for a class of small molecule PD-L1 inhibitors, complementing the antibody-based intellectual property held by Bristol-Myers Squibb and others. The existence of such patents indicates ongoing research and development into diverse modalities for targeting the PD-1/PD-L1 pathway. What are the Potential Infringement Considerations for US 9,592,208? Potential infringement of US 9,592,208 would arise if a third party develops, manufactures, uses, offers for sale, or sells a compound that falls within the scope of the patent’s claims, or uses such a compound in a method claimed by the patent, without authorization from Bristol-Myers Squibb. Key considerations for infringement analysis include: Claim Construction: The interpretation of the patent claims (claim construction) is paramount. This involves determining the precise meaning and scope of each term in the claims, often through litigation. Comparison to Claimed Structures: For composition of matter claims, a third-party compound infringes if it is structurally identical or equivalent to a compound claimed. This involves analyzing the Markush structure and its defined substituents against the structure of the accused compound. Method of Use Infringement: For method claims, infringement occurs if a third party actively performs the claimed method (e.g., treats a patient with cancer using a compound that inhibits PD-L1) or induces or contributes to such infringement. Importation: Importing infringing products into the United States also constitutes infringement. Doctrine of Equivalents: Even if a compound does not literally fall within the claim language, it may infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result. This is particularly relevant for Markush claims where minor structural variations might be present. Companies developing small molecule inhibitors targeting the PD-1/PD-L1 pathway would need to conduct thorough freedom-to-operate (FTO) analyses to ensure their compounds and methods do not infringe on existing patents like US 9,592,208. This involves searching for and analyzing relevant patent literature, including expired patents that may still provide a basis for ongoing protection through method of use claims. The broad nature of Markush claims, as found in US 9,592,208, can create a wide berth of potential infringement. Analyzing the specific R groups and core structures defined in the patent is critical for any FTO assessment. What is the Commercial Significance of this Patent? The commercial significance of US 9,592,208 is derived from its potential to protect novel therapeutic agents for a highly lucrative and rapidly growing market. The PD-1/PD-L1 pathway has emerged as a cornerstone of modern oncology, with checkpoint inhibitors generating billions of dollars in annual revenue for pharmaceutical companies. Key aspects of its commercial significance include: Market Potential: The target indication, cancer treatment, represents a massive global market. Success in this area offers substantial commercial rewards. First-Mover Advantage: Patents grant exclusivity, allowing the patent holder to be the sole provider of the claimed technology for a defined period (typically 20 years from the filing date). This allows for recoupment of significant R&D investments and establishment of market share. Blockbuster Drug Potential: Compounds targeting the PD-1/PD-L1 pathway have demonstrated the ability to achieve blockbuster status (annual sales exceeding $1 billion). The patent’s claims cover a class of compounds with the potential for such success. Pipeline Asset Value: For Bristol-Myers Squibb, patents like US 9,592,208 are crucial for maintaining a robust drug pipeline and securing future revenue streams. They signal ongoing innovation and investment in a critical therapeutic area. Licensing and Collaboration Opportunities: Patents can be licensed to other companies, generating revenue through royalties and upfront payments. They can also serve as a basis for strategic partnerships and collaborations. Deterrent to Competitors: The existence of strong patent protection, including a broad Markush claim, can deter competitors from developing similar compounds or entering the market with infringing products, thereby preserving the patent holder’s competitive advantage. While the specific commercial success of any compound derived directly from this patent is contingent on further development, clinical trials, and regulatory approval, the patent itself holds significant value by protecting a key therapeutic mechanism in a highly profitable disease area. Key Takeaways Compound and Method Claims: US 9,592,208 protects a genus of small molecule compounds designed to inhibit the PD-1/PD-L1 pathway, as well as methods of using these compounds for treating diseases, primarily cancer. Broad Chemical Scope: The Markush claims cover a wide array of chemical structures, offering significant breadth in protecting potential drug candidates. Therapeutic Target: The patent targets the PD-1/PD-L1 axis, a critical regulator of immune responses, with significant implications for cancer immunotherapy. Commercial Value: The patent is commercially significant due to the immense market potential of PD-1/PD-L1 inhibitors and the protection it offers against market entry by competitors for a specified period. Competitive Landscape: The PD-1/PD-L1 inhibitor space is highly competitive, with multiple companies holding extensive patent portfolios covering antibodies and small molecules. Frequently Asked Questions What is the expiration date of United States Patent 9,592,208? Patent US 9,592,208 was granted on March 14, 2017. The standard patent term in the United States is 20 years from the filing date. Assuming a priority date from its earliest filing, its expiration would typically be in the early 2030s, barring any patent term extensions (PTE) or adjustments. Can generic versions of drugs covered by this patent be developed? Generic development of small molecule drugs covered by US 9,592,208 would only be possible after the patent expires or if a generic manufacturer successfully challenges the patent’s validity or obtains a license. For compounds claimed by this patent, generic entry would be restricted by the patent term. Does this patent cover antibody-based PD-1 inhibitors like nivolumab? No, US 9,592,208 specifically claims small molecule compounds defined by a Markush structure. Antibody-based inhibitors, such as nivolumab, are distinct in their chemical nature and are protected by different patents covering biologics. What are the specific types of cancer this patent is intended to treat? While the patent does not list specific cancers exhaustively within its claims, it broadly covers "cancer" and diseases mediated by PD-L1. Based on the known therapeutic applications of PD-1/PD-L1 inhibitors, this would include but not be limited to melanoma, non-small cell lung cancer, renal cell carcinoma, and bladder cancer, among others where this pathway is dysregulated. How does this patent relate to other PD-1/PD-L1 inhibitor patents? US 9,592,208 contributes to the overall intellectual property strategy in the PD-1/PD-L1 inhibitor field by covering a class of small molecule inhibitors. This complements other patents held by Bristol-Myers Squibb and competitors that protect antibody therapeutics, different small molecule scaffolds, and specific methods of treatment or combinations. It represents a distinct but related area of protection within the broader immunotherapy landscape. Citations [1] Bristol-Myers Squibb Company. (2017). United States Patent US 9,592,208. U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-002	May 11, 2018		RX	Yes	No	9,592,208*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

PCT Information
PCT Filed	March 30, 2012	PCT Application Number:	PCT/US2012/031340
PCT Publication Date:	October 04, 2012	PCT Publication Number:	WO2012/135561

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	085749	⤷ Start Trial
Argentina	124661	⤷ Start Trial
Australia	2012236357	⤷ Start Trial
Brazil	112013024430	⤷ Start Trial
Canada	2831600	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,592,208

Which drugs does patent 9,592,208 protect, and when does it expire?

Summary for Patent: 9,592,208